REN and malignant hypertension: It will be recalled that seminal studies from Laragh group revealed that abnormal activation of the renin–angiotensin system (RAS) plays a crucial role in the pathophysiology of malignant hypertension [9,10] and the notion that inappropriate activation of the RAS importantly contributes to the transition to the malignant phase was later confirmed by many other studies [11–14].